Did genes or ancestry make the Manning brothers? Why not both?
The field of sports genomics is rife with argument, starting with the simple question of what athleticism even is. For every study that shows a relationship between ribonucleic acids and raising trophies, another contradicts it. The interplay of slow- and fast-twitch fibers that makes balance, concentration, spatial awareness, these are not traits like hair color. Maybe someday genomics will be a useful predictor of whether you're growing a Hall of Famer at your kitchen table, but for the moment, it's overneat to the point of uselessness. If you're going down the rabbit hole of athleticism, at least go down a more intriguing path that embraces the messiness and mystery: genealogy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Collaboration Is Key To The Future Of Cancer Research And Innovation
Linda De Jesus, IDT Vice President and General Manager, Global Head of Commercial. Advances in next generation sequencing (NGS) technologies have enabled cancer research innovations like improvements in minimal residual disease (MRD) identification and the discovery of drugs that target genetic tumor abnormalities. These approaches were backed by collaborations between developers and genomic technology suppliers who combined their scientific expertise and manufacturing capabilities to accelerate the pace of cancer research for the patients they serve. When forming these alliances, cancer researchers are faced with a growing selection of NGS providers, some of which pitch what they consider to be disruptive solutions. These alternative solutions can, at times, focus more on speed and cost—a concept suggesting that quicker insights will reduce the need for additional sequencing, equating to more tests performed and rapid breakthroughs to market. No doubt, speed and efficiency matter. But prioritizing 'fast and new' can be detrimental to driving cancer research innovation. In my opinion, a more effective approach is partnership: entering strategic relationships with genomic providers that have the quality, knowledge and capabilities to design optimized assays that generate reproducible results, making them your trusted partner from discovery through clinical development. How Researchers Are Leveraging Partnerships The key to obtaining better, more actionable insights from NGS assays is to create flexible yet optimized end-to-end workflows from library preparation to data analysis. These workflows are all customized to the experiment at hand and led by an NGS expert who has both strong in-house capabilities and a track record of collaborating with partners that help solve labs' biggest challenges. This is not just about forming one strong alliance with an innovative technology provider—it's also about benefiting from that partner's wider network of collaborators. To streamline research, developers can work hand in hand with technology providers to create or optimize customized panels, adapters, library prep and other reagents for the most robust assay to fit their needs. Among the many applications where it's vital to prioritize quality over speed in cancer research is the identification of MRD. Researchers use NGS to identify MRD by measuring circulating cell-free DNA (cfDNA) through the presence of low-frequency mutations that are known to be associated with the cancer type being studied. The MRD research and testing field is consistently growing as new genes of interest are found in blood cancers such as leukemia, lymphoma and myeloma. To support this research, developers are engaging with vendors to design new panels. Collaborations between the developers and their strategic partners also help establish high standards and metrics, so laboratories can maintain consistent data, resulting in the most reliable and confident insights possible. The most effective collaborations benefit from enhancing their capabilities by embracing outside expertise. For instance, my company, Integrated DNA Technologies (IDT), deploys continuous improvement strategies. We also have a strategic alliance with a Bio-IT company so customers can pair insights obtained from secondary analysis platforms with tertiary variant annotation and reporting software to contextualize data for both known and newly discovered variants. Recently, we also formed an innovation hub to foster innovative ideas and advancements, and foster customer collaboration. By combining expertise, manufacturing and technology capabilities, genomics providers can stay at the forefront of emerging technologies, strengthen their own capabilities to support customers, and enhance their market knowledge. Best Practices When Entering Partnerships With NGS Technology Providers Cancer researchers must collaborate with their NGS suppliers to foster a more business-minded approach to accelerating innovation. To accomplish this, developers must view their suppliers as strategic partners and work in unison to leverage their expertise, domain knowledge and supply chain management. This comprehensive approach is beneficial for researchers: It ensures a supplier's capabilities closely align with their lab's scientific objectives, resulting in increased productivity, lower inventory costs and overall savings. View them as more than a transactional arrangement so that each party can appreciate the value of partnership to advance the industry and overcome hurdles with technology sharing, regulatory roadblocks and overall cost burden. As the partnership matures, there will be an upside, such as realizing the economic and business benefits that working together brings. When evaluating expertise, experience matters. Third-party validation, proof-of-concept, comparative testing and a diverse customer base are a few ways to assess an NGS supplier's track record. These factors help distinguish a partner that can provide quality, expertise and consistency over a vendor that displays disruptive new technology. While not all partnerships will be a good fit, in order for them to succeed, it must be a win-win and provide a synergistic benefit that fills an industry, market or technology gap, solves a customer problem, or accelerates therapeutic development. Conclusion Strategic partnerships between developers and suppliers will continue to drive important innovations in NGS for cancer research. But to truly drive maximum benefit from these partnerships, developers who want to maximize insights should prioritize expertise and quality of data over disruptive new technology focused solely on speed and cost. For cancer patients awaiting new therapies, the stakes are too high. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Associated Press
an hour ago
- Associated Press
GenBio CSO Professor Lindsay Brown Drills Down into the Autism Spectrum Disorder
The Global Burden of Disease 2021 report estimated that 1 in 127 people or 61.8 million were on the autism spectrum (ASD) globally 'I know of nobody who is purely autistic, or purely neurotypical. Even God has some autistic moments, which is why the planets spin.'— Jerry Newport ALISO VIEJO, CA, UNITED STATES, June 30, 2025 / / -- The Global Burden of Disease 2021 report estimated that 1 in 127 people or 61.8 million were on the autism spectrum ( ASD ) globally, leading to a burden of 11.7 million disability- adjusted life years. The non-fatal health burden of ASD as a developmental condition includes persistent difficulties in social interaction, challenges with sensory perception, and repetitive behaviours. The causes of ASD are very complex, including genetic and epigenetic changes, environmental factors such as increased maternal age, maternal characteristics of metabolic syndrome, changes in the gut microbe-brain axis, medication exposure such as the antidepressant valproic acid and the effects of infection, oxidative stress and inflammation. These causes underlie the heterogeneity in the aetiology, phenotype and outcome of ASD. Treatment for ASD mainly includes ongoing behavioural and educational interventions but there are no pharmacological interventions that target the core ASD symptoms. The gut-brain axis allows the brain to regulate gastrointestinal function while the gut microbiome regulates the brain by immune, neuroendocrine and vagal pathways. Molecules that regulate the brain derived from the gut microbiome include lipopolysaccharide, short- chain fatty acids, vitamins including the B-group, neurotransmitters such as pro-inflammatory cytokines, intestinal hormones and tryptophan metabolites such as 5-hydroxytryptamine (5-HT) and kynurenine. Enteroendocrine cells (EC) in the gut produce 95% of the body's 5-HT; chronic exposure to the gut microbiota increases 5-HT synthesis by an increased EC proliferation. Changes to the gut microbiome may also be relevant to maternal influences on ASD. These changes are not unique to ASD but may contribute to many brain health issues including depression, anxiety and neurodegenerative disorders. Modifying gut microbiota in ASD by dietary modulation may decrease gastro-intestinal dysfunction and improve behaviour. However, eating disorders combined with tantrums and behavioural problems are common in ASD children so dietary modulation will not always be feasible. The importance of the gut microbiota is shown by Microbiota Transfer Treatment as a potential therapy for ASD; in 18 children, follow-up after 2 years showed that improvements in gastro-intestinal symptoms were maintained while further improvements in autism-related symptoms were measured. Prebiotics and synbiotics may produce improvements for some behavioural and gastrointestinal symptoms in ASD but the evidence should be expanded. Further, there is evidence for benefits of probiotics in children with ASD showing behavioural and gastrointestinal improvements. Dietary nutraceuticals include the anthocyanins as the purple, red and blue colours in many fruits, including Queen Garnet and Davidson's plums. The anthocyanins produce anti- inflammatory and antioxidant responses and change the gut microbiome. Treatment with an anthocyanin-containing extract from blueberries decreased neuroinflammation and gut inflammation, modulated the gut microbiota and improved 5-HT concentrations in the gut and prefrontal cortex to ameliorate autism-like behaviours in a valproic acid mouse model of autism. Clinical trials of anthocyanins in patients with cognitive impairment in mild Alzheimer's disease have shown improved vascular responses. While these limited clinical trials with anthocyanins in mental health issues are important, they need to be extended to long-term but expensive trials as part of treatment for ASD patients. There are many changes that could improve life outcomes for autistic people and further research on chronic interventions with anthocyanins during pregnancy and in childhood would seem to be justified. Todd D. Sonoga GenBio Inc. +1 949-705-8021 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
an hour ago
- Yahoo
Scientists Discovered a New Creature That Exists Between Life and Not-Life
Here's what you'll learn when you read this story: Viruses typically aren't considered 'alive,' as many core biological functions are outsourced to their hosts. But a newly discovered organism appears to straddle the line between virus and cell. Like a virus, this new organism 'Sukunaarchaeum mirabile' outsources some functions to its host, but can still create its own ribosomes and RNA. Its genome is also surprisingly small, and is roughly half the size (238,000 base pairs) of the next-smallest archaeal genome. At first glance, creating a definition for 'life' seems somewhat straightforward. Sentient animals all the way down to single-celled organisms capable of reproduction are welcome on the tree of life, but there are other organisms that challenge this understanding, like viruses. Because virus don't grow, reproduce on their own, or make their own energy, they're typically excluded from definitions of life. But once a virus infects a host, it's immensely active, and can be responsible for world-altering events (see: Spanish flu, ebola, COVID-19, and so on). However, life is complicated, and this controversial categorization of 'life' and 'not life' can have gray areas in which organisms appear to defy the expectations of both camps. Recently, scientists found a new member of this head-scratching cadre. In a new paper published on the bioRxiv server, researchers in Canada and Japan outlined how they identified a new cellular entity that appeared to straddle the typical definitions of a virality and cellular life. Currently named 'Sukunaarchaeum mirabile' (after a deity in Japanese mythology known for its small stature), this entity contains the necessary genes to create its own ribosomes and messenger RNA—something your typical virus lacks. But like a virus, it offloads certain biological functions onto its host and it appears singularly obsessed with replicating itself. 'Its genome is profoundly stripped-down, lacking virtually all recognizable metabolic pathways, and primarily encoding the machinery for its replicative core: DNA replication, transcription, and translation,' the authors wrote. 'This suggests an unprecedented level of metabolic dependence on a host, a condition that challenges the functional distinctions between minimal cellular life and viruses.' Led by Ryo Harada, a molecular biologist from Dalhousie University in Halifax, Nova Scotia, the team chanced upon this strange creature while studying the bacterial genome of the marine plankton Citharistes regius. Within the genomic data, Harada and his team found a loop of DNA that didn't match with any known species. They eventually determined that the organism belonged to the domain Archaea—a group associated with prokaryotic cells, but from which eukaryotic cells (i.e. you and me) ultimately descended a couple billion years ago. Perhaps the most remarkable feature of Sukunaarchaeum is its extreme genome reduction, with only 238,000 base pairs of DNA. Viruses, as Live Science points out, can contain many hundreds of thousands more base pairs, and can even reach up into the millions. As for fellow archaea, the smallest known complete genome within this group stretches to 490,000 base pairs, meaning that Sukunaarchaeum contains less than half the number of base pairs posessed by even the smallest archaeal genome. 'The discovery of Sukunaarchaeum pushes the conventional boundaries of cellular life and highlights the vast unexplored biological novelty within microbial interactions,' the authors wrote. 'Further exploration of symbiotic systems may reveal even more extraordinary life forms, reshaping our understanding of cellular evolution.' You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
